- Home
- ZBRA vs JAZZ Comparison
ZBRA vs JAZZ Comparison
Compare ZBRA & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBRA | JAZZ |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 16.1B |
| IPO Year | 1995 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ZBRA | JAZZ |
|---|---|---|
| Price | $364.72 | $248.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $321.88 | $217.57 |
| AVG Volume (30 Days) | ★ 812.9K | 804.5K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.54 | 7.17 |
| Revenue | ★ $5,396,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $13.27 | $6.22 |
| Revenue Next Year | $5.43 | $7.68 |
| P/E Ratio | $47.72 | ★ $34.77 |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $199.05 | $123.89 |
| 52 Week High | $386.23 | $266.38 |
Technical Indicators
Market Signals| Indicator | ZBRA | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 50.26 |
| Support Level | $350.36 | $237.05 |
| Resistance Level | $386.23 | $265.05 |
| Average True Range (ATR) | 9.74 | 7.19 |
| MACD | -4.60 | -0.44 |
| Stochastic Oscillator | 31.95 | 40.94 |
Price Performance
Historical ComparisonAbout ZBRA Zebra Technologies Corporation
Zebra Technologies is the largest provider of automatic identification and data capture technology to enterprises. Its solutions include barcode printers and scanners, mobile computers, and workflow optimization software. The firm primarily serves the retail, transportation logistics, manufacturing, and healthcare markets, designing custom solutions to improve efficiency at its customers.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.